Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer 'buys big into CAR-T' with $80M upfront + 10% equity stake + up to $185M per target — characterized as Pfizer's catch-up move against Novartis and Juno.
Pfizer transferred its 16-asset allogeneic CAR-T portfolio (originating from the 2014 Cellectis deal) to Allogene Therapeutics, retaining a 25% stake.
BioPharma Dive retrospective on the tangled Pfizer-Cellectis-Servier-Allogene chain, noting that the 2014 deal seeded a category that has yet to deliver…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Pfizer paid Cellectis $80M upfront plus a 10% equity stake (~$31M) and up to $185M per Pfizer-selected target in milestones across 15 Pfizer-chosen and 4 jointly-developed CAR-T targets. Strategically transformative—Pfizer's largest 2014 immuno-oncology entry and the foundation for what later became Allogene Therapeutics.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Cellectis SA (this deal) | 2014 | $2.9B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2014 deals · Pfizer Inc. deals · Hematology deals